| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
Recombinant Human Serum Albumin does not target a specific receptor; its primary function is to maintain plasma osmotic pressure and transport hormones, lipids, and other substances. Its main physiological function is to regulate plasma pH and maintain plasma oncotic pressure. It does not contain animal-derived components and can provide a safer choice for serum-free culture medium.
|
|---|---|
| ln Vitro |
In vitro, rHSA is used as a transport protein in cell culture media to support cell growth and viability. It is a non-animal alternative to fetal bovine serum (FBS) or bovine serum albumin (BSA). It is a major component of blood and has important functions such as maintaining pH balance and supporting cell growth. Recombinant HSA derived from rice endosperm (OsrHSA) is a safe, cost-effective, and reliable source to meet the medical needs of patients worldwide.
|
| ln Vivo |
In vivo, rHSA is used clinically as an alternative to plasma-derived HSA for the management of hypovolemia, hypoalbuminemia, and ascites in cirrhotic patients. It maintains plasma osmotic pressure and has important functions such as maintaining pH balance and supporting cell growth. A phase Ib study aims to assess the safety, tolerability, and PK/PD profiles of rHA in cirrhotic patients with ascites.
|
| Enzyme Assay |
A cell-free binding assay for HSA is not typical. However, the binding affinity of various small molecules (e.g., warfarin, ibuprofen) to rHSA can be measured using fluorescence spectroscopy (e.g., using the probe dansylsarcosine or warfarin). Increasing concentrations of the test compound are added to a fixed concentration of rHSA. The change in fluorescence intensity (ex/em = 295/340 nm for tryptophan) is monitored. The binding constant (Ka) is calculated from the quenching data.
|
| Cell Assay |
rHSA is used in cell culture to replace FBS or BSA. Cells (e.g., HEK293, CHO) are seeded in serum-free medium supplemented with rHSA (0.5-5 g/L). Cell growth and viability are assessed by cell counting and MTT assay over 3-7 days. Cytokine release or antibody production can be measured if using expression systems. rHSA supports cell proliferation without the risk of animal-derived contaminants.
|
| Animal Protocol |
rHSA has been studied in animal models of liver cirrhosis and ascites. A standard protocol: male Sprague-Dawley rats are treated with carbon tetrachloride (CCl4) to induce cirrhosis. When ascites develops, rats are administered rHSA (0.5-1 g/kg) intravenously once daily for 7 days. Plasma volume is measured using Evans blue dilution. Ascites volume is quantified. Renal function (urine output, sodium excretion) is assessed. The efficacy is compared to plasma-derived HSA.
|
| ADME/Pharmacokinetics |
rHSA has a molecular weight of approximately 66.5 kDa. It should be stored as a lyophilized powder at 2-8degC or -20degC. The product is stable for 2-3 years when stored properly. Reconstituted solutions should be used within 24-48 h. rHSA has a long circulation half-life (approximately 19 days in humans) due to FcRn-mediated recycling. It is primarily metabolized in the liver and excreted renally.
|
| Toxicity/Toxicokinetics |
rHSA derived from rice is a safe and well-tolerated product. In clinical trials, no significant adverse events have been reported, and it has a similar safety profile to plasma-derived HSA. It does not carry the risk of viral or prion contamination associated with human plasma-derived products. Rice-derived rHSA is considered to have low immunogenicity. No specific toxicity concerns have been identified.
|
| References |
[1]. K Kobayashi, et al. The development of recombinant human serum albumin. Ther Apher. 1998 Nov;2(4):257-62.
|
| Additional Infomation |
rHSA is an FDA-approved biological product (e.g., Albutein, Flexbumin) for clinical use as a plasma volume expander. Recombinant HSA derived from rice (OsrHSA) has completed clinical trials for cirrhosis-associated ascites. It offers a safe, cost-effective alternative to plasma-derived HSA, with advantages including batch-to-batch consistency and freedom from animal-derived components. This product is for research use and therapeutic applications.
|
| Appearance |
White to light yellow solid powder
|
|---|---|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~50 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
